|
|
Capricorn Pharma
is a specialty oral
drug delivery
systems company engaged
in the innovation, development,
commercialization, and
manufacture of pharmaceutical products.
Modified Release
Technology Platforms In different dosage
forms - mini tablets, beads, layered, dry coated and regular
tablets.
Medicated Chewing
Gums
World-class expertise
in gum base, gums,
pharmaceutical
actives, taste-masking, and
flavor delivery development
-
&
manufacturing
KOR-TR —
KORPULSE —
KOR-OPS —
KORLAYER
—
Timed,
programmed and
site-specific
release
Pulsatile release
Multiparticulate
dispersion with
osmotic
agents
Multi layered and/or dry coated tablet for COMBO drugs
Orally
Disintegrating Dosage Forms (ODD)
Rapid Dissolve tablet
forms
ODT
Two layer KOR-Koat
Tabs
Healthee Chew
Cubes
Chew Tabs
Flash Melt
Beads
Micro Encapsulation
EAB Technology- Enhanced Dissolution
EAB technology can be
used to accelerate onset of action,
lower dosage levels,
and improve absorption; all of which can enhance product performance, extend patent life and increase market share.
Micro Encapsulation
Process
Coacervation
Spray Systems
Fluidization
Adsorption
Complexation
Others
Spray Drying
Spray Congealing
Polymer Coating
Hot Melt Coating
Extrusion
Micro
emulsions
Capricorn Pharma
Inc.
Leaders in Drug
Delivery Systems
6900 English Muffin
Way, Frederick, MD- 21703, USA
Tel: (301) 696 1452,
Fax: (301) 696 1424
EAB technology
Accelerates Drug Absorption
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
Oropharynx
Nasopharynxs
Esophagus
Stomach
Colon
Small
Intestine
Pulsatile Release
Sustained Release #1
Sustained Release #2 |
|
 |
 |
|
• |
Press Release
04 Aug 08
Capricorn Pharma Inc and Teva Pharmaceuticals USA
enter into agreement.
FREDERICK, MD. (BUSINESS WIRE)
S. Rao Cherukuri --- Founder, President and Chief Executive Officer of
Capricorn Pharma Inc., announced today that his company has an agreement
with Teva Pharmaceuticals USA, to develop products using Capricorn's proprietary KORKOAT technology platform.
KORKOAT beads accommodate high drug loads; Modified drug release can be achieved by
incorporating release-modifying agents inside the bead, in the coating or in both.
"We are honored and pleased to have this agreement with Teva," Mr. Cherukuri said
"We are proud of our technologies, which offer flexible solutions to difficult
formulation challenges. We believe this agreement further validates our commercialized
oral drug delivery technology platforms and Capricorn's proprietary encapsulation processes."
Terms of the agreement were not disclosed.
|
|
 |
|
|
 |
|
|
|
Capricorn Pharma Inc. |
 6900
English Muffin Way, Frederick,Maryland 21703
T: 301-696-1452
F: 301-696-1424 |
|
Email:
srcherukuri@capricornpharma.com |
|
